Recombinant Mycobacterium bovis BCG

被引：73
|
作者：
Bastos, Reginaldo G. [2 ]
Borsuk, Sibele [1 ]
Seixas, Fabiana K. [1 ]
Dellagostin, Odir A. [1 ]
机构：
[1] Univ Fed Pelotas, Ctr Biotecnol, Mol Biol Lab, BR-96010900 Pelotas, RS, Brazil
[2] Washington State Univ, Dept Vet Microbiol & Pathol, Pullman, WA 99164 USA
来源：
VACCINE | 2009年 / 27卷 / 47期
关键词：
Mycobacterium bovis BCG; Recombinant BCG; Heterologous expression; Immunomodulator; BACILLUS-CALMETTE-GUERIN; HUMAN-IMMUNODEFICIENCY-VIRUS; SURFACE PROTEIN-A; CELLULAR IMMUNE-RESPONSES; EXPRESSING INTERFERON-GAMMA; RESPIRATORY-SYNDROME-VIRUS; GLUTATHIONE-S-TRANSFERASE; CYTOTOXIC T-LYMPHOCYTES; LYME-DISEASE VACCINE; PROTECTIVE IMMUNITY;
D O I：
10.1016/j.vaccine.2009.08.044
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The Bacillus Calmette-Guerin (BCG) is an attenuated strain of Mycobacterium bovis that has been broadly used as a vaccine against human tuberculosis. This live bacterial vaccine is able to establish a persistent infection and induces both cellular and humoral immune responses. The development of mycobacterial genetic systems to express foreign antigens and the adjuvanticity of BCG are the basis of the potential use of this attenuated mycobacterium as a recombinant vaccine. Over the years, a range of strategies has been developed to allow controlled and stable expression of viral, bacterial and parasite antigens in BCG. Herein, we review the strategies developed to express heterologous antigens in BCG and the immune response elicited by recombinant BCG constructs. In addition, the use of recombinant BCG as an immunomodulator and future perspectives of BCG as a recombinant vaccine vector are discussed. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码：6495 / 6503
页数：9
相关论文
共 50 条
  • [31] Stable Expression of Lentiviral Antigens by Quality-Controlled Recombinant Mycobacterium bovis BCG Vectors
    Hart, Bryan E.
    Asrican, Rose
    Lim, So-Yon
    Sixsmith, Jaimie D.
    Lukose, Regy
    Souther, Sommer J. R.
    Rayasam, Swati D. G.
    Saelens, Joseph W.
    Chen, Ching-ju
    Seay, Sarah A.
    Berney-Meyer, Linda
    Magtanong, Leslie
    Vermeul, Kim
    Pajanirassa, Priyadharshini
    Jimenez, Amanda E.
    Ng, Tony W.
    Tobin, David M.
    Porcelli, Steven A.
    Larsen, Michelle H.
    Schmitz, Joern E.
    Haynes, Barton F.
    Jacobs, William R., Jr.
    Lee, Sunhee
    Frothingham, Richard
    CLINICAL AND VACCINE IMMUNOLOGY, 2015, 22 (07) : 726 - 741
  • [32] Enhanced antimycobacterial response to recombinant Mycobacterium bovis BCG expressing latency-associated peptide
    Marshall, BG
    Wangoo, A
    O'Gaora, P
    Cook, HT
    Shaw, RJ
    Young, DB
    INFECTION AND IMMUNITY, 2001, 69 (11) : 6676 - 6682
  • [33] Differentiation between Mycobacterium bovis BCG-vaccinated and M-bovis-infected cattle by using recombinant mycobacterial antigens
    Buddle, BM
    Parlane, NA
    Keen, DL
    Aldwell, FE
    Pollock, JM
    Lightbody, K
    Andersen, P
    CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1999, 6 (01) : 1 - 5
  • [34] ULTRASTRUCTURAL CHARACTERISTICS OF MYCOBACTERIUM-BOVIS BCG AND MYCOBACTERIUM-LEPRAE
    BINKHUYSEN, F
    DAS, PK
    INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES, 1982, 50 (01) : 76 - 82
  • [35] New Recombinant Mycobacterium bovis BCG Expression Vectors: Improving Genetic Control over Mycobacterial Promoters
    Kanno, Alex I.
    Goulart, Cibelly
    Rofatto, Henrique K.
    Oliveira, Sergio C.
    Leite, Luciana C. C.
    McFadden, Johnjoe
    APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 2016, 82 (08) : 2240 - 2246
  • [36] Recombinant ArgF PLGA nanoparticles enhances BCG induced immune responses against Mycobacterium bovis infection
    Ni, Jiamin
    Liu, Yiduo
    Hussain, Tariq
    Li, Miaoxuan
    Liang, Zhengmin
    Liu, Tianlong
    Zhou, Xiangmei
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 137
  • [37] Role for Gr-1+ Cells in the Control of High-Dose Mycobacterium bovis Recombinant BCG
    Panas, Michael W.
    Letvin, Norman L.
    CLINICAL AND VACCINE IMMUNOLOGY, 2014, 21 (08) : 1120 - 1127
  • [38] Advances and challenges in recombinant Mycobacterium bovis BCG-based HIV vaccine development: lessons learned
    Kilpelainen, Athina
    Maya-Hoyos, Milena
    Saubi, Narcis
    Soto, Carlos Y.
    Joseph Munne, Joan
    EXPERT REVIEW OF VACCINES, 2018, 17 (11) : 1005 - 1020
  • [39] Cellular Immune Responses to Recombinant Mycobacterium bovis BCG Constructs Expressing Major Antigens of Region of Difference 1 of Mycobacterium tuberculosis
    Shaban, Kholoud
    Amoudy, Hanady A.
    Mustafa, Abu S.
    CLINICAL AND VACCINE IMMUNOLOGY, 2013, 20 (08) : 1230 - 1237
  • [40] Double Recombinant Mycobacterium bovis BCG Strain for Screening of Primary and Rationale-Based Antimycobacterial Compounds
    Singh, Vandana
    Biswas, Rajesh Kumar
    Singh, Bhupendra N.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (03) : 1389 - 1396
12345